Aguiar Zdovc, J.; Hanžel, J.; Kurent, T.; Sever, N.; Koželj, M.; Smrekar, N.; Novak, G.; Štabuc, B.; Dreesen, E.; Thomas, D.;
et al. Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model. Pharmaceutics 2021, 13, 1587.
https://doi.org/10.3390/pharmaceutics13101587
AMA Style
Aguiar Zdovc J, Hanžel J, Kurent T, Sever N, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D,
et al. Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model. Pharmaceutics. 2021; 13(10):1587.
https://doi.org/10.3390/pharmaceutics13101587
Chicago/Turabian Style
Aguiar Zdovc, Jurij, Jurij Hanžel, Tina Kurent, Nejc Sever, Matic Koželj, Nataša Smrekar, Gregor Novak, Borut Štabuc, Erwin Dreesen, Debby Thomas,
and et al. 2021. "Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model" Pharmaceutics 13, no. 10: 1587.
https://doi.org/10.3390/pharmaceutics13101587
APA Style
Aguiar Zdovc, J., Hanžel, J., Kurent, T., Sever, N., Koželj, M., Smrekar, N., Novak, G., Štabuc, B., Dreesen, E., Thomas, D., Vovk, T., Ostanek, B., Drobne, D., & Grabnar, I.
(2021). Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model. Pharmaceutics, 13(10), 1587.
https://doi.org/10.3390/pharmaceutics13101587